Northwest Biotherapeutics Presents Updated Survival Data from Phase III Trial of DCVax®-L For Glioblastoma Using Individual Patient Level Data in Multiple Independent Analyses

Phase 3positiveDCVax-LPositive

AI Analysis

Summary

Northwest Biotherapeutics presented updated Phase III trial data for DCVax-L in glioblastoma at the British Neuro-Oncology Annual Meeting, showing that original survival extension analysis was likely underestimated based on individual patient level data in multiple independent analyses.

Clinical Trial Data

Phase

Phase III

Primary Endpoint

Met

Outcome Details

Updated survival data from Phase III trial presented; original analysis of survival extension was likely underestimated

Importance:7/10

Sentiment:

0.70

Phase 3 dataglioblastomaimmunotherapysurvival benefitconference presentation

Related Companies

$NWBO

Read the original article

Published by PR Newswire Biotech on July 8, 2026 6:42 PM

Read Original